SA
Go ProLog In
SYRE
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
11 analysts·Moderate coverage
75
Score
11 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
11100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$49.00
-34.6%
Consensus
$90.00
+20.1%
Bull
$107.00
+42.8%
12-Month Target Range11 analysts
$49.00$90.00$107.00
Current $74.92Consensus
Current Price
$74.92
Upside to Consensus
$15.08

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+88.11%
EPS—
FY2028
Rev+20.00%
EPS—
FY2029
Rev+25008.40%
EPS—

Earnings Surprises

Recent Analyst Actions

May 12, 2026Deutsche Bank
Spyre Therapeutics price target raised to $102 from $86 at Deutsche Bank
Target:$102.00
+34.4%from $75.89
May 6, 2026Stifel Nicolaus
Spyre Therapeutics price target raised to $107 from $92 at Stifel
Target:$107.00
+50.7%from $71.01
Apr 14, 2026Robert W. Baird
Spyre Therapeutics price target raised to $90 from $65 at Baird
Target:$90.00
+42.2%from $63.27
Apr 14, 2026Wells Fargo
Spyre Therapeutics price target raised to $90 from $50 at Wells Fargo
Target:$90.00
+42.2%from $63.27
Apr 14, 2026Deutsche Bank
Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank
Target:$88.00
+39.1%from $63.27
Apr 13, 2026Raymond James
Spyre Therapeutics initiated with a Strong Buy at Raymond James
Target:$80.00
+26.4%from $63.27
Apr 13, 2026Wedbush
Spyre Therapeutics price target raised to $80 from $65 at Wedbush
Target:$80.00
+26.4%from $63.27
Apr 13, 2026Leerink Partners
Spyre Therapeutics price target raised to $106 from $49 at Leerink
Target:$106.00
+67.5%from $63.27
Apr 13, 2026BTIG
Spyre Therapeutics price target raised to $98 from $70 at BTIG
Target:$98.00
+54.9%from $63.26
Apr 13, 2026Jefferies
Spyre Therapeutics price target raised to $85 from $47 at Jefferies
Target:$85.00
+31.2%from $64.78
Mar 16, 2026William Blair
Leerink Partners Reiterates Outperform Rating on Spyre (SYRE): 'today's update reflects SYRE's strong clinical execution'
Target:$49.00
+12.1%from $43.70
Dec 17, 2025Mizuho Securities
Spyre Therapeutics initiated with an Outperform at Mizuho
Target:$53.00
+60.3%from $33.06
Sep 26, 2025Deutsche Bank
Spyre Therapeutics initiated with a Buy at Deutsche Bank
Target:$43.00
+164.8%from $16.24
Nov 12, 2024Stifel Nicolaus
Spyre (SYRE) PT Raised to $71 at Stifel
Target:$71.00
+99.9%from $35.52
Oct 17, 2024Robert W. Baird
Baird Reiterates Outperform Rating on Spyre (SYRE)
Target:$50.00
+54.5%from $32.37
Oct 15, 2024Wells Fargo
Wells Fargo Reiterates Overweight Rating on Spyre (SYRE)
Target:$40.00
+30.5%from $30.66
May 10, 2024BTIG
Spyre Therapeutics price target raised to $40 from $32 at BTIG
Target:$40.00
+13.7%from $35.19

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance